We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Showcases Solutions for Laboratories of the Future

By LabMedica International staff writers
Posted on 30 Jul 2024
Print article
Image: Roche’s booth at ADLM 2024 provides a view of the future of laboratory and point-of-care diagnostics (Photo courtesy of Roche)
Image: Roche’s booth at ADLM 2024 provides a view of the future of laboratory and point-of-care diagnostics (Photo courtesy of Roche)

Roche (Basel, Switzerland) is showcasing a laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo. Attendees can experience how Roche's growing portfolio of integrated systems and data solutions optimizes resources and simplifies and streamlines operations while driving better health outcomes.

Focusing on key attributes of science-based leadership, operational simplicity, and patient-centric partnership, Roche is featuring its newest innovations in-booth at ADLM. These include the future cobas Mass Spec solution designed to be a total end-to-end solution for clinical mass spectrometry testing with the goal of seamless integration into the routine laboratory. Roche is also highlighting the new CCM Vertical, a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas connection modules. Also featuring at ADLM 2024 is the cobas liat system which brings gold-standard PCR technology to the point of care, providing results within 20 minutes across a growing menu of assays.

The cobas pure integrated solutions which combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs are also being highlighted at the meeting. Additionally, Roche is featuring the cobas eplex system, a rapid syndromic molecular diagnostic solution that has been updated with new features across all aspects of the workflow process, alongside the cobas 5800 is a compact, fully automated molecular PCR-testing solution with a comprehensive menu of assays. Visitors to the Roche booth can also experience the cobas LightCycler PRO qPCR system which is designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories with an improved user experience.

At ADLM 2024, Roche is also presenting its full array of navify digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. Roche is also presenting eight Roche Idea Lab segments in its booth, where experts will discuss topics such as mass spectrometry, digital solutions, respiratory testing, and the use of high-medical-value assays when treating Alzheimer's and heart failure. Scientific industry workshops include "Laboratorians' Perspectives on Evaluation and Implementation of Alzheimer's CSF Assays" and "Making a Subjective Sepsis Diagnosis More Objective: The Role of AI-based Sepsis Medical Algorithms in Empowering Healthcare Decisions."

"Laboratorians strive to deliver trusted, timely test results to patients with greater effectiveness and efficiency. Our latest generation of cobas solutions are proven to deliver seamless integration of systems and data to support these efforts," said Brad Moore, president and CEO of Roche Diagnostics North America. "We are excited to share these next-generation solutions, which are the building blocks for future laboratories, and are eager to partner with our customers so that they can both do more with less and deliver the best possible outcomes for patients."

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.